corpse is during the first 24 hours after death. By day 5, the amount of infectious virus has decreased by 96.48%. If proper biosafety precautions and personal protective equipment are used to handle the corpse during autopsy or preparation for burial or cremation, we believe that the burial or cremation process is unlikely to spread disease.

This study was partly supported by the Health and Medical Research Fund (grant no. HMRF COVID-190115 to M.P. and S.A.V.), and Commissioned Research on Control of Infectious Diseases (phase III and IV) from the Health and Medical Research Fund (M.P.).

About the Author
Dr. Valkenburg is a viral immunologist at the HKU-Pasteur Research Pole, University of Hong Kong, Hong Kong, China. Her research interests include immune correlates for influenza and severe acute respiratory syndrome coronavirus 2.

References

Guillain-Barré Syndrome Associated with COVID-19 Vaccination

Shih-Chieh Shao,1 Chien-Ho Wang,1 Kai-Cheng Chang, Ming-Jui Hung, Hui-Yu Chen, Shu-Chen Liao

Author affiliations: Keelung Chang Gung Memorial Hospital, Keelung, Taiwan (S.-C. Shao, C.-H. Wang, M.-J. Hung, S.-C. Liao); National Cheng Kung University College of Medicine, Tainan, Taiwan (S.-C. Shao, K.-C. Chang); Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan (K.-C. Chang, H.-Y. Chen); Chang Gung University College of Medicine, Taoyuan (M.-J. Hung, S.-C. Liao)

DOI: https://doi.org/10.3201/eid2712.211634

We conducted a multi-institutional study in Taiwan and a systematic review of the literature for reports of Guillain-Barré syndrome after coronavirus disease vaccination. This condition, mostly the classic form and the acute inflammatory demyelinating polyneuropathy subtype, has been reported in 39 cases and has occurred within 2 weeks of vaccine administration.

Guillain-Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy with a ~5% mortality rate, has an incidence worldwide of 0.81–1.91 cases/100,000 person-years (1). GBS has been

1These authors contributed equally to this article.
reported to be associated with coronavirus disease (COVID-19) vaccination, but a comprehensive summary regarding this rare adverse event is still lacking. To determine clinical features of GBS associated with COVID-19 vaccination, we conducted hospital-based investigations in Taiwan along with a systematic review of published case reports.

We analyzed electronic medical records data from Taiwan’s largest multi-institutional healthcare system, including 9 branches of Chang Gung Memorial Hospital (2), where healthcare workers received first-priority COVID-19 ChAdOx1-S vaccine (Oxford/AstraZeneca, https://www.astrazeneca.com) starting March 22, 2021. We included healthcare workers vaccinated during March 22–May 31 and followed them for 30 days after vaccination. We identified GBS cases on the basis of code G610 from the International Classification of Disease, 10th Revision, Clinical Modification, or spontaneous adverse drug reaction reporting systems within the hospitals. Two authors (C.H.W. and S.C.L.) confirmed diagnosis and classification of GBS cases through chart reviews (3,4). This study was approved by the Institutional Review Board of Chang Gung Medical Foundation (approval no. 202101087B0).

To summarize clinical features of published cases from literature, we searched PubMed and Embase for reports posted through August 17, 2021, using relevant key terms such as “COVID-19,” “Guillain-Barré syndrome,” and “vaccine” with suitable MeSH terms. Two independent reviewers (S.C.S., C.H.W.) performed the study selection and data extraction; a third-reviewer (S.C.L.) settled any differences between them. We excluded cases with coexisting COVID-19 or preexisting GBS. We included only publications with reports of clinical features related

Figure. Systematic review of published literature in study of Guillain-Barré syndrome associated with coronavirus vaccination, 2021. GBS, Guillain-Barré syndrome.

Published articles in PubMed, n = 49

Published literature in Embase, n = 58

Additional records from reference lists, n = 1

Records screened, n = 108

- Study duplicates, n = 27
- Records not related to study question, n = 45
- Other publication types (e.g., reviews, editorials, commentaries), n = 17

Full-text articles assessed for eligibility, n = 19

No reports of clinical features of GBS, n = 2

Studies for this systematic review, n = 17
to GBS. We described basic characteristics, laboratory data, pathologic reports, treatment patterns, and prognosis of GBS cases associated with COVID-19 vaccination. The study protocol of this systematic review is published on PROSPERO (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=265479).

We included 18,269 healthcare workers (mean age 40.6 years, range 18–87 years; 67.5% were women) who received ChAdOx1-S vaccine during the study period. After these 18,257 first-dose and 544 second-dose vaccinations, we identified 1 GBS case after a first dose of ChAdOx1-S vaccine in 1 of the hospitals participating in the study.

After a systematic review of published literature (Figure), we included 17 publications reporting an additional 38 cases of GBS related to COVID-19 vaccination (India, 10 cases; United Kingdom, 11 cases; Mexico, 7 cases; United States, 3 cases; France, 1 case; Italy, 3 cases; Malta, 1 case; Turkey, 1 case; and Qatar, 1 case) (Appendix Table, https://wwwnc.cdc.gov/EID/article/27/12/21-1634-App1.pdf). Including the case in Taiwan, these 39 cases occurred in persons with a mean age of 57.8 (range 20–86) years; 56.4% were male. Most of the reported case-patients received ChAdOx1-S (25/39), followed by BNT162b2 (12/39) (Pfizer-BioNTech, https://www Pfizer.com), Ad26.COV2.S (1/39) (Johnson & Johnson, https://www.jnj.com), and CoronaVac (1/39) (Sinovac Biotech, http://www.sinovac.com). The GBS rate after COVID-19 vaccination ranged from 1.8 to 53.2 cases/1 million doses. The initial symptoms of GBS included myalgia (12/39), paraparesis (5/39), quadriplegic (22/39), paresthesia (28/39), and facial palsy (23/39), and symptoms of dysautonomia also were observed during hospitalizations (3/39). The average time from vaccination to symptom onset was 11.3 days. A total of 34 case-patients received lumbar puncture; 30 had manifestations of albuminocytologic dissociation in the cerebrospinal fluid.

On the basis of the clinical diagnostic classification of GBS, we found that most case-patients had the classic form (22/39), followed by bilateral facial palsy with paresthesia (12/39), the paraparetic form (4/39), and GBS–Miller Fisher syndrome overlap variant (1/39). We defined all classic and paraparetic forms of GBS (26/26) as level 1 or 2 on the basis of the Brighton criteria (5). We identified the GBS subtype in 33/39 cases by electrophysiological examination; most reported case-patients had a diagnosis of acute inflammatory demyelinating polynuropathy (23/33), followed by acute motor and sensory axonal neuropathy (4/33) and acute motor axonal neuropathy (3/33). For GBS management, 33 case-patients received intravenous immunoglobulin and 2 received plasmapheresis. One case-patient died; 9 case-patients required mechanical ventilation during hospitalization. The scores on the GBS disability scale (5) were only available for 30 cases; 12 scored >4 (i.e., indicating bedridden or chair-bound status) during follow-up or after discharge.

Similar to previous reviews on GBS associated with COVID-19, we found that both COVID-19 and COVID-19 vaccination mostly cause the classic form of GBS (under the clinical diagnosis classification) and the acute inflammatory demyelinating polynuropathy subtype (based on electrodiagnostic features) within 2 weeks of infection or vaccination (6–8). However, the bilateral facial palsy with paresthesia variant and initial onset symptoms of facial diplegia were more frequently found in GBS case-patients after COVID-19 vaccination.

Case series and reports can indicate safety issues and outline clinical features of diseases, but they cannot establish robust causal relationships between COVID-19 vaccination and GBS. Despite the benefits (e.g., increase in the number of persons not susceptible to infection and decrease in severe outcomes after infection) of COVID-19 vaccination far outweighing the potentially severe adverse events after infection (9), our findings highlight the need for vigilance in patients with neurologic symptoms after COVID-19 vaccination and for postvaccination surveillance programs to assess causality of GBS.

Acknowledgments
We thank Cheng-Yang Hsieh and Wen-Mei Cheng for their insightful opinions on this study.

About the Author
Dr. Shao is a clinical pharmacist at Keelung Chang Gung Memorial Hospital. His research interests include the use of systematic review and meta-analysis to summarize current best evidence on clinical topics, specifically in regard to complications in COVID-19 patients.

References
3. Uncini A, Vallat JM, Jacobs BC. Guillain-Barré syndrome in
Limited Protection of Inactivated SARS-CoV-2 Vaccine against Wild-Type Strain and Variants of Concern


Address for correspondence to: Shu-Chen Liao, Department of Emergency Medicine, Keelung Chang Gung Memorial Hospital, 222 Maijin Rd, Keelung, Taiwan; email: ermdsusang@gmail.com

In vitro determination of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies induced in serum samples from recipients of the CoronaVac vaccine showed a short protection period against the original virus strain and limited protection against variants of concern. These data provide support for vaccine boosters, especially variants of concern circulate.

Circulation of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants capable of evading vaccine-derived protection is challenging the efficacy of coronavirus disease (COVID-19) vaccines (1). The inactivated SARS-CoV-2 vaccine CoronaVac (Sinovac Biotech, http://www.sinovac.com), 1 of 2 COVID-19 vaccines licensed in Thailand, has been widely administered to health care workers. Clinical studies show CoronaVac efficacy against symptomatic COVID-19 ranging from 51% (Brazil) to 65.9% (Chile) and 100% against severe illness and illness requiring hospitalization (2,3). However, data on CoronaVac efficacy against variants of concern are very limited. Our study was approved by the Research Ethics Review Committee, Faculty of Medicine, Chulalongkorn University (Bangkok, Thailand) and recorded in the Thai Clinical Trial Registry (TCTR20210325003). Investigators adhered to the United States Department of Defense AR 70–25 policies for protection of human subjects.

For this study, we enrolled 207 health care workers in Thailand who were fully vaccinated with 2 doses of CoronaVac (0.5 mL/dose, 2–4 wk between doses); all had received their first dose during February 22–March 12, 2021. Median age was 39 (interquartile range 30–51) years of age; 67 (49.6%) were men. Among study participants, 58 (28%) provided blood samples only at baseline (when the first dose was administered), 93 (44.0%) both at baseline and 2–3 weeks after the second dose, and 56 (27.0%) at baseline and at 2–3 weeks and 10–12 weeks after the second dose. Using an in vitro system (Appendix, https://wwwnc.cdc.gov/EID/article/27/12/21-1772-App1.pdf), we evaluated the ability of the serum of CoronaVac...
# Guillain-Barré Syndrome Associated with COVID-19 Vaccination

## Appendix

### Appendix Table. Clinical features of GBS associated with COVID-19 vaccination

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>GBS rate</td>
<td>1/18,801</td>
<td>NA</td>
<td>NA</td>
<td>4/712,050</td>
<td>4/712,050</td>
</tr>
<tr>
<td>Vaccine</td>
<td>ChAdOx1 (1st dose)</td>
<td>ChAdOx1 (1st dose)</td>
<td>ChAdOx1 (1st dose)</td>
<td>ChAdOx1 (1st dose)</td>
<td>ChAdOx1 (1st dose)</td>
</tr>
<tr>
<td>Age, y</td>
<td>41</td>
<td>72</td>
<td>62</td>
<td>54</td>
<td>20</td>
</tr>
<tr>
<td>Sex</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
</tr>
<tr>
<td>Vaccination to symptom onset, d</td>
<td>7</td>
<td>21</td>
<td>8</td>
<td>12</td>
<td>22</td>
</tr>
<tr>
<td>Initial symptoms (dysautonomia)</td>
<td>Paresthesia, facial diplegia (No)</td>
<td>Myalgia, paresthesia, dysarthria, ascending paralysis, facial diplegia (No)</td>
<td>Paresthesia, ascending paralysis (No)</td>
<td>Paresthesia, facial diplegia (No)</td>
<td>Paresthesia, facial diplegia (No)</td>
</tr>
<tr>
<td>Albuminocytologic dissociation (CSF protein, mg/dl)</td>
<td>Yes (159.8)</td>
<td>Yes (62.0)</td>
<td>Yes (90.0)</td>
<td>Yes (162.6)</td>
<td>Yes (123.2)</td>
</tr>
<tr>
<td>Clinical classification</td>
<td>Bilateral facial palsy with paresthesia</td>
<td>Classic GBS</td>
<td>Classic GBS</td>
<td>Bilateral facial palsy with paresthesia</td>
<td>Bilateral facial palsy with paresthesia</td>
</tr>
<tr>
<td>Electro-diagnosis</td>
<td>Equivocal</td>
<td>NA</td>
<td>NA</td>
<td>Equivocal</td>
<td>Equivocal</td>
</tr>
<tr>
<td>Brighton criterion†</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Antiganglioside antibody</td>
<td>IVIG (0.4g/kg/day for 5 days)</td>
<td>Anti-GM3 IgM positive</td>
<td>IVIG (0.4g/kg/day for 5 days)</td>
<td>Prednisolone (60mg for 5 days)</td>
<td>Prednisolone (60mg for 5 days)</td>
</tr>
<tr>
<td>Treatment (drug dose)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Outcome (GBS disability scale‡)</td>
<td>Survived (1)</td>
<td>Survived (NA)</td>
<td>Survived (5)</td>
<td>No</td>
<td>Survived (NA)</td>
</tr>
<tr>
<td>Author name (country)</td>
<td>GBS rate</td>
<td>Age, y</td>
<td>Sex</td>
<td>Vaccine</td>
<td>Vaccination to symptom onset, d</td>
</tr>
<tr>
<td>----------------------</td>
<td>----------</td>
<td>-------</td>
<td>-----</td>
<td>---------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Maramattom BV, et al (India) (4)</td>
<td>7/1,200,000 (ChAdOx1 nCoV-19)</td>
<td>55</td>
<td>M</td>
<td>ChAdOx1 (1st dose)</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td></td>
<td>43</td>
<td>F</td>
<td>ChAdOx1 (1st dose)</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td></td>
<td>67</td>
<td>F</td>
<td>ChAdOx1 (1st dose)</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>53</td>
<td>F</td>
<td>ChAdOx1 (1st dose)</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>68</td>
<td>F</td>
<td>ChAdOx1 (1st dose)</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td></td>
<td>70</td>
<td>M</td>
<td>ChAdOx1 (1st dose)</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td></td>
<td>69</td>
<td>F</td>
<td>ChAdOx1 (1st dose)</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td></td>
<td>69</td>
<td>F</td>
<td>ChAdOx1 (1st dose)</td>
<td>13</td>
</tr>
<tr>
<td>Oghenbor O., et al (USA) (5)</td>
<td>NA</td>
<td>86</td>
<td>F</td>
<td>BNT162b2 (1st dose)</td>
<td>1</td>
</tr>
<tr>
<td>Patel SU, et al (UK) (6)</td>
<td>NA</td>
<td>37</td>
<td>M</td>
<td>ChAdOx1 (1st dose)</td>
<td>14</td>
</tr>
<tr>
<td>Márquez Loza AM, et al (USA) (7)</td>
<td>NA</td>
<td>60</td>
<td>F</td>
<td>Ad26.COV2.S (1st dose)</td>
<td>10</td>
</tr>
<tr>
<td>Author name (country)</td>
<td>GBS rate</td>
<td>Age, y</td>
<td>Sex</td>
<td>Vaccine</td>
<td>Vaccination to symptom onset, d</td>
</tr>
<tr>
<td>--------------------------</td>
<td>----------</td>
<td>--------</td>
<td>-----</td>
<td>---------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>Waheed S, et al (USA) (8)</td>
<td>NA</td>
<td>82</td>
<td>F</td>
<td>BNT162b2 (1st dose)</td>
<td>14</td>
</tr>
<tr>
<td>Razok A, et al (Qatar) (9)</td>
<td>NA</td>
<td>73</td>
<td>M</td>
<td>BNT162b2 (2nd dose)</td>
<td>16</td>
</tr>
<tr>
<td>Nasuelli NA, et al (Italy) (10)</td>
<td>NA</td>
<td>59</td>
<td>M</td>
<td>ChAdOx1 (1st dose)</td>
<td>10</td>
</tr>
<tr>
<td>Bonifacio GB, et al (UK) (11)</td>
<td>NA</td>
<td>66</td>
<td>M</td>
<td>ChAdOx1 (1st dose)</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>43</td>
<td>M</td>
<td></td>
<td>ChAdOx1 (1st dose)</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>51</td>
<td>M</td>
<td></td>
<td>ChAdOx1 (1st dose)</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>71</td>
<td>F</td>
<td></td>
<td>ChAdOx1 (1st dose)</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>53</td>
<td>M</td>
<td></td>
<td>ChAdOx1 (1st dose)</td>
<td>8</td>
</tr>
<tr>
<td>McKeen N, et al (Malta) (12)</td>
<td>NA</td>
<td>48</td>
<td>M</td>
<td>ChAdOx1 (1st dose)</td>
<td>10</td>
</tr>
<tr>
<td>James J, et al (India) (13)</td>
<td>NA</td>
<td>60</td>
<td>M</td>
<td>ChAdOx1 (1st dose)</td>
<td>11</td>
</tr>
<tr>
<td>Author name (country)</td>
<td>GBS rate</td>
<td>Age, y</td>
<td>Sex</td>
<td>Vaccine</td>
<td>Vaccination to symptom onset, d</td>
</tr>
<tr>
<td>----------------------</td>
<td>----------</td>
<td>-------</td>
<td>-----</td>
<td>---------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>66 M ChAdOx1 (1st dose)</td>
<td>12</td>
<td>Ascending paralysis, paresthesia Urinary retention, BP fluctuation</td>
<td>Yes (64)</td>
<td>Classic GBS</td>
<td>AIDP</td>
</tr>
<tr>
<td>54 F ChAdOx1 (1st dose)</td>
<td>13</td>
<td>Quadripareisis, paresthesia, dysphagia (No)</td>
<td>NA</td>
<td>Classic GBS</td>
<td>AIDP</td>
</tr>
<tr>
<td>García-Grimshaw M, et al (Mexico)</td>
<td>7/3,890,250 (BNT162b2)</td>
<td>28</td>
<td>Facial diplegia (No)</td>
<td>Yes (67.1)</td>
<td>Bilateral facial palsy with paresthesia</td>
</tr>
<tr>
<td>33 M BNT162b2 (1st dose)</td>
<td>12</td>
<td>Paresthesia, quadripareisis (No)</td>
<td>Yes (64)</td>
<td>Classic GBS</td>
<td>AIDP</td>
</tr>
<tr>
<td>53 F BNT162b2 (1st dose)</td>
<td>6</td>
<td>Quadripareisis (No)</td>
<td>No (15)</td>
<td>Classic GBS</td>
<td>AMAN</td>
</tr>
<tr>
<td>72 M BNT162b2 (1st dose)</td>
<td>4</td>
<td>Quadripareisis (No)</td>
<td>NA</td>
<td>Classic GBS</td>
<td>AMAN</td>
</tr>
<tr>
<td>31 M BNT162b2 (1st dose)</td>
<td>11</td>
<td>Quadripareisis (No)</td>
<td>NA</td>
<td>Classic GBS</td>
<td>AIDP</td>
</tr>
<tr>
<td>67 F BNT162b2 (1st dose)</td>
<td>4</td>
<td>Quadripareisis (No)</td>
<td>No (30)</td>
<td>Classic GBS</td>
<td>AMAN</td>
</tr>
<tr>
<td>81 F BNT162b2 (1st dose)</td>
<td>3</td>
<td>Quadripareisis (No)</td>
<td>Yes (414)</td>
<td>Classic GBS</td>
<td>AIDP</td>
</tr>
<tr>
<td>Trimboli M, et al (Italy) (15)</td>
<td>NA</td>
<td>25</td>
<td>F BNT162b2 (2nd dose)</td>
<td>5</td>
<td>Paraparesis, paresthesia (No)</td>
</tr>
<tr>
<td>Tutar NK, et al (Turkey) (16)</td>
<td>NA</td>
<td>76</td>
<td>M CoronaVac (2nd dose)</td>
<td>5</td>
<td>Myalgia, ascending paralysis (No)</td>
</tr>
<tr>
<td>Author name (country)</td>
<td>GBS rate</td>
<td>Age, y</td>
<td>Sex</td>
<td>Vaccine</td>
<td>Vaccination to symptom onset, d</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------</td>
<td>--------</td>
<td>-----</td>
<td>---------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Scendoni R, et al (Italy) (17)</td>
<td>NA</td>
<td>82</td>
<td>F</td>
<td>BNT162b2 (2nd dose)</td>
<td>15</td>
</tr>
</tbody>
</table>

*AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor and sensory axonal neuropathy; BP, blood pressures; CSF, cerebral spinal fluid; GBS, Guillain-Barré Syndrome; IVIG, Intravenous immunoglobulin; MFS, Miller-Fisher Syndrome; NA, not available.
†The Brighton Criteria is a diagnostic tool for GBS, ranging from level 1 (highest level) to level 4 (lowest level) of diagnostic certainty by assessing the patient’s clinical presentation, cerebrospinal fluid data and nerve conduction velocity findings.
‡GBS Disability Scale grades the patient’s functional disability from 0 (healthy) to 6 (dead).

References


